Lung Cancer | Specialty

PD-L1 Inhibitor Delivers Rapid, Durable Responses in Advanced NSCLC

September 29th 2013

A phase I study has shown remarkable and durable responses with the engineered monoclonal antibody MPDL3280A in metastatic non-small cell lung cancer, including tumors with squamous and adenocarcinoma histology.

Dr. Novello on the Gray Areas in Lung Cancer Care

September 27th 2013

Silvia Novello, MD, PhD, assistant professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses some of the "gray areas" that require more research for the treatment of patients with lung cancer.

Dr. Brahmer Discusses Managing Immunotherapy AEs

September 26th 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the management of adverse events (AEs) from treatment with immunotherapies.

Dr. Pass on Blood-Based Markers in Lung Cancer

September 25th 2013

Harvey I. Pass, MD, Stephen E. Banner Professor of Thoracic Oncology, Vice-Chair Research, Department of Cardiothoracic Surgery, Division Chief, General Thoracic Surgery, NYU Langone Medical Center, discusses blood-based markers in lung cancer.

Dr. Scagliotti on Treating EGFR-Mutated Tumors with Afatinib

September 23rd 2013

Giorgio V. Scagliotti, MD, PhD, head, Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses treating epidermal growth factor receptor- (EGFR) mutated tumors with afatinib.

Chemotherapy Questions Linger in Early NSCLC

September 23rd 2013

The optimal use of adjuvant chemotherapy for patients with early-stage non-small cell lung cancer remains unresolved, with several clinical trials under way in Europe aimed at identifying ways to better select patients for treatment

Dr. Herbst on Targeting PD-1 and PD-L1 in Lung Cancer

September 19th 2013

Roy S. Herbst, MD, PhD, professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the differences of targeting PD-1 and PD-L1 when treating patients with lung cancer.

Learn More About Robotic Thoracic Surgery Offered at UC Davis

September 18th 2013

The section of General Thoracic Surgery at UC Davis is offering Robotic Thoracic Surgery to further enhance our top regional minimally invasive thoracic surgery program.

Dr. Bunn Discusses Afatinib in Lung Cancer

September 17th 2013

Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor (EGFR) mutation.

Dr. Novello on Targeting the MAGE-A3 Protein

September 16th 2013

Silvia Novello, MD, PhD, assistant professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses immunotherapy and targeting the MAGE-A3 protein in lung cancer.

Dr. Mok Discusses Developing Lung Cancer Treatments

September 12th 2013

Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.

Dr. Wakelee Discusses the AVAPERL Trial

August 30th 2013

Heather Wakelee, MD, an assistant professor at the Stanford University School of Medicine and member of the Stanford Cancer Institute, discusses the results of the AVAPERL trial.

Comprehensive Lung Cancer Screening at UC Davis

August 28th 2013

UC Davis CLSP is a multidisciplinary program for comprehensive lung cancer screening.

Dr. Gaspar on Reducing Neurotoxicity in Lung Cancer

August 26th 2013

Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses reducing neurotoxicity in small cell lung cancer patients.

Dr. Pass on the Challenges of Treating Mesothelioma

August 23rd 2013

Harvey I. Pass, MD, from the NYU Langone Medical Center, discusses the challenges of treating patients with mesothelioma.

New Point-of-Care App, PulmaCalc PPO, Predicted Post-operative Pulmonary Function Calculator

August 22nd 2013

Brought to you by the UC Davis Section of General Thoracic Surgery: PulmaCalc PPO is a predicted post-operative pulmonary function calculator

Conclusion: Final Thoughts on Treatment Advances in NSCLC

August 21st 2013

Selecting a First-Line EGFR Inhibitor in NSCLC

August 21st 2013

GALAXY-1 Trial: Investigation of Hsp90 Inhibition in NSCLC

August 21st 2013

Novel Immunotherapy Combinations in NSCLC

August 21st 2013